Logo

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab- biosimilar) in Finland

Share this

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab- biosimilar) in Finland

Shots:

  • Amgevita is indicated to treat chronic inflammatory diseases such as moderate-to-severe RA- IBD and psoriasis
  • Amgen Biosimilar Amgevita- is a novel adalimumab’s biosimilar to be marketed in Finland. On 23 Mar- 2017 Amgevita received EU approval for inflammatory diseases in adults
  • In 2013- Orion marketed first infliximab’s biosimilar in Finland post its marketing approval. Amgevita is the third biosimilar marketed by Orion- and novel drug injected at home

/ article | Ref: Orion | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions